Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuromuscular
•
Neurohospitalist
How do you treat checkpoint inhibitor induced myasthenia gravis?
Is recurrence treated differently?
Related Questions
How frequently do you re-evaluate AChR and MuSK antibodies in patients with clinical and electrodiagnostic evidence of seronegative myasthenia gravis?
When do you test for myasthenia antibodies beyond AChR and MuSK?
In which clinical scenarios do you find medial and lateral plantar sensory or mixed nerve conduction studies to be valuable?
At what hemoglobin level would you consider blood transfusion in a patient with acute brain injury?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
What types of cardiac conduction abnormalities would lead you to avoid using tricyclic antidepressants?
How do you counsel patients with mild congenital myopathy about exercise limitations?
Do you always biopsy patients who present with classic skin findings of dermatomyositis?
What postural change in FVC is suggestive of respiratory muscle weakness?
When do you consider testing autoimmune antibodies for axonal polyneuropathies without clear etiology?
